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Abstract
Development of pharmacologic agents that protect podocytes from injury is a critical strategy for the treatment of kidney
glomerular diseases. Retinoic acid reduces proteinuria and glomerulosclerosis in multiple animal models of kidney diseases.
However, clinical studies are limited because of significant side effects of retinoic acid. Animal studies suggest that all trans
retinoic acid (ATRA) attenuates proteinuria by protecting podocytes from injury. The physiological actions of ATRA are
mediated by binding to all three isoforms of the nuclear retinoic acid receptors (RARs): RARa, RARb, and RARc. We have
previously shown that ATRA exerts its renal protective effects mainly through the agonism of RARa. Here, we designed and
synthesized a novel boron-containing derivative of the RARa-specific agonist Am580. This new derivative, BD4, binds to
RARa receptor specifically and is predicted to have less toxicity based on its structure. We confirmed experimentally that
BD4 binds to RARa with a higher affinity and exhibits less cellular toxicity than Am580 and ATRA. BD4 induces the
expression of podocyte differentiation markers (synaptopodin, nephrin, and WT-1) in cultured podocytes. Finally, we
confirmed that BD4 reduces proteinuria and improves kidney injury in HIV-1 transgenic mice, a model for HIV-associated
nephropathy (HIVAN). Mice treated with BD4 did not develop any obvious toxicity or side effect. Our data suggest that BD4
is a novel RARa agonist, which could be used as a potential therapy for patients with kidney disease such as HIVAN.
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Introduction
Glomerular kidney disease is a major cause of End-Stage-Renal-
Disease (ESRD) in the United States [1]. Treatment options for
these diseases are scarce. Steroids and immunosuppressive
medications are first-line treatments for glomerular diseases.
However, resistant cases are frequently observed and side effects
from the treatment are multiple. Treatment of glomerular diseases
with angiotensin converting enzyme inhibitors or angiotensin
receptor blockers reduces proteinuria and slows the progression of
kidney disease. However, they only provide partial protection.
Therefore, it is important to identify new treatment targets or
regimes.
HIV-associated nephropathy (HIVAN), characterized by col-
lapsing focal segmental glomerulosclerosis (FSGS), is a leading
cause of kidney disease in young African Americans [2]. Although
suppression of viral replication with antiretroviral therapy alters
the course of the kidney disease, a specific treatment for this
disease is not available, and many patients with HIVAN still
progress to ESRD [3]. Podocyte injury is a major cause of kidney
diseases, including HIVAN. Podocyte dedifferentiation and
proliferation is a unique feature observed in HIVAN [4]–[5].
HIV-infected podocytes lose differentiation markers including
synaptopodin and WT1 [6]. In vitro, HIV infection causes
podocyte proliferation and dedifferentiation through activation
of MAPK and Stat3 pathways [7]. Transgenic mice expressing
HIV-1 gene in podocytes develop kidney disease similar to
HIVAN [8]. Therefore, prevention or reversal of podocyte injury
is an important strategy to treat HIVAN. So far, no drugs are
available to specifically prevent or reverse podocyte injury as a
treatment option for glomerular diseases.
Retinoids are derivatives of vitamin A and have multiple cellular
functions including inhibition of proliferation, induction of cell
differentiation, regulation of apoptosis, and inhibition of inflam-
mation [9]. During kidney development, retinoic acid affects
tubulogenesis and nephron number [10]. In addition to their
established benefits for treatment of a variety of cancers, retinoids
have been shown to protect against renal injury in multiple
experimental models of kidney diseases [11]. In rat models of acute
and chronic mesangioproliferative glomerulonephritis, retinoids
preserve renal function, decrease albuminuria, and reduce
glomerular and tubular damage [12][13]. In a rat model of
puromycin aminonucleoside-induced nephrosis, retinoids prevent
proteinuria by protecting podocytes from injury [14] [15].
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in rats with chronic glomerulonephritis [16]. ATRA treatment also
reduces lymphoproliferation and glomerulonephritis in MRL/lpr
mice [17]. The protective effects of retinoids have also been reported
inmicewithdiabetic nephropathy[18] and inan antibody-mediated
model of podocye injury [19]. ATRA can restore the expression of
podocyte differentiation markers including nephrin, podocin, and
synaptopodin in vivo [19]. Recently, we found that ARTA reduces
proteinuria and glomerulosclerosis in the HIV-1 transgenic mouse
(Tg26), an animal model of HIVAN [20], by inhibiting cell
proliferation and restoring differentiation markers in HIV-infected
podocytes [20]. In addition, ATRA was shown to inhibit HIV-
induced podocyte proliferation through activation of MAPK
phosphatase 1 (MKP1) leading to the inhibition of MAPK phos-
phorylation [21]. These studies provide a strong support for using
retinoic acid to treat glomerular diseases where podocytes injury is a
prominent factor in disease pathogenesis. A phase II clinical trial is
currently ongoing to examine the effect of ATRA in patients with
glomerular diseases with podocyte injury including steroid-resistant
minimal change disease, FSGS, and HIVAN (NIDDK website).
However, clinical use of ATRA is challenging due to its side effect
profile,whichincludesdifferentiation syndrome [22],depression and
psychosis, severe acne, dryness of skin and mucosal membranes,
inflammatory bowel diseases, and teratogenicity.
Our recent studies suggest that retinoic acid improves kidney
glomerular diseases and protects podocytes from injury by
activating retinoic acid receptor-a (RARa) [23]. We found that
Am580, a RARa-specific agonist, induces podocyte differentiation
in vitro and attenuates kidney injury of Tg26 mice in vivo [23].
Knockout of RARa aggravates kidney injury in Tg26 mice. Taken
together, these data strongly support using RARa agonists for the
treatment of kidney disease. It is critical to identify new specific
agonists for RARa that possess the therapeutic function, but
eschew the undesirable side effects of retinoic acid.
Several studies suggest that the toxicity of structural analogs of
retinoic acid may be considerably reduced if a heterocyclic ring is
incorporated. For instance, the presence of a substituted chromene
moiety in the retinoic acid backbone, such as in the oxaretinoids,
considerably reduced the toxicity of the compounds [24] [25] [26]
[27] [27]. Based on these findings, we have synthesized a novel
RARa agonist, BD4, and characterized its efficacy for the
treatment of kidney disease in Tg26 mice.
Results
1. Synthesis of a heteroaraotinoid—BD4
To generate BD4, we made the following modifications to
Am580. We introduced an acid-bioisosteres group—boronic acid
and a 3-substituted-2-phenyl-2H-chromene derivatives to protects
isomerization of alkene spacers at 9, 13, 15 position of ATRA. No
prior description of the biological effects of these compounds has
been reported. The structural comparison between BD4 and
Am580 is shown in Figure 1. Synthesis of BD4 is summarized in
Figure 2. Our compound BD4 is unique as this is the first boronic-
acid containing retinoids. By incorporating oxygen heteroatoms
and replacing one of the gem-dimethyl groups in the tetrahy-
dronaphthalene ring of Am580 we decreased the potential toxicity
of Am580 by retarding metabolic oxidation. To avoid protease-
mediated hydrolysis and improve the stability of the BD4 we
introduced amide isosteres trans-double bonds in place of amide
bonds in Am580.
All retinoids and synthetic heteroarotinoids reported to date
contain acid groups. The use of boron atoms in pharmaceutical
drug design has a high potential for discovery of new biological
activities [28]. The boron atom has a vacant orbital and inter-
converts with ease between the neutral and anionic hybridization
states, which generates a new stable interaction between the boron
atom and a donor molecule through a covalent bond [29].
Therefore, it is anticipated that boron atoms introduced into
biologically active molecular frameworks could interact with a
target protein not only through hydrogen bonds but also through
covalent bonds, and this interaction might produce potent
biological activity, a concept that is well supported by the
literature [30]. Among various synthetic boron compounds,
considerable attention has been placed on boronic acid-containing
peptides such as Velcade and DPP-IV inhibitors [31].
We screened our small focused library. Unlike the commonly
employed approach of high-throughput screening of large libraries
to identify lead compounds that elicit a desired phenotypic effect,
we were utilizing a Limited Rational Design approach, which
means rather than screening 10,000-100,000 arrayed compounds
we generated a small library of only about 40-50 to identify lead
compounds. We used the synthesis strategies for boron-containing
unnatural amino acids and peptides and heterocycles as described
previously [32] [33] [34] [35] [36].
Figure 1. Synthesis of RARa agonist BD4. We designed and synthesized a novel RARa agonist, BD4, by making a bridge of a functional group
(trans double bond) between hydrophobic chromene rings and benzoic acid or acid isosteres. The functional group was designed not only to
increase the efficacy but also to reduce the toxicity of compounds. These modifications also increase the specificity for retinoic acid receptor isoforms.
Characteristic features of BD4 are as follows: a) Our compound BD4 is oxaretinoid; b) Incorporation of oxygen heteroatoms to replace one of the
gem-dimethyl groups in the tetrahydronaphthalene ring of Am580 decrease the toxicity by retarding metabolic oxidation; c) To protect against
protease-mediated hydrolysis of amides bonds found in Am580, we introduced trans-double bond as amide isosteres in BD4, which is more resistant
to proteolysis; d) Substitution of boronic acid and ester in BD4 in place of acids generates a more biologically active molecular frameworks, which
allows BD4 to interact with a target protein through both hydrogen bonds and covalent bonds. This interaction is predicted to produce more potent
biological activity.
doi:10.1371/journal.pone.0027945.g001
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and Am580
First, we confirmed that BD4 binds specifically to RARa. Since
we were unable to label BD4 directly by either tritium or
fluorescence tagging, we used a modified fluorometric assay that
has been previously described [37] to assess BD4 binding to
RARa. Using this fluorometric binding assay we confirmed that
BD4 binds to RARa with an affinity of 1465 nM (Figure 3A),
which is in the range of what has been reported previously for
Am580 [38]. We also performed competitive binding assays for
BD4 and Am580 and for BD4 and ATRA. We found that 5-to-10
fold of Am580 or ATRA was required to induce a 40–50%
competitive inhibition of BD4 binding to a GST-tagged RARa.
This confirms that BD4 binds to RARa with a higher affinity than
Am580 or ATRA (Figure 3B).
3. BD4 is not toxic to podocytes in culture
Next, we compared the cellular toxicity among ATRA, Am580,
and BD4 in podocytes by trypan blue staining to determine cell
death. Podocytes were cultured with ATRA, Am580, and BD4 at
different concentrations for 24 hours in serum free medium. Cell
death was quantified by trypan blue staining. We found that BD4
had significantly lower cell toxicity than ATRA and Am580 at
1 mM and 10 mM (Figure 4).
4. BD4 promotes podocyte differentiation in vitro
To assess the biologic effect of BD4 on podocyte differentiation,
we used a conditionally immortalized murine podocyte cell line
which has been used extensively to study podocyte differentiation
in vitro [39]. These podocytes express a temperature-sensitive T
antigen, which is stable at 33uC and inactive at 37uC. T-antigen
activates cell proliferation at 33uC. At 37uC, T-antigen is inacti-
vated and cells grow slowly and express podocyte differentiation
markers to some extent (partial differentiation). Our previous
studies suggest that ATRA can induce further differentiation of
these podocytes at 37uC by stimulating the expression of podocyte
differentiation markers including synaptopodin, nephrin and
Wilm’s Tumor 1 (WT1). Thus, we compared the effects of BD4,
Figure 2. Reaction scheme to synthesize BD4. Compound B was synthesized from compound A by organocatalytic domino oxa-Michael/aldol
reaction using organocatlyst 1. Compound B was further derivatized to compound BD4 by using Wittig reactions using Compound C as Wittig salt.
doi:10.1371/journal.pone.0027945.g002
Figure 3. RARa binding assay. A fluorometric binding assay was performed as described in the method. A. The scatter curve was built between
different concentrations of BD4 and percentage BD4 binding to calculate the KD. A representative curve is shown from four independent
experiments. KD=1465 nM, n=4. B. Competitive binding assays were performed between BD4 and Am580 or BD4 and ATRA. No significant
inhibition of binding was observed at 1:1 ratio. However, a 40% inhibition of BD4 binding was observed when Am580 to BD4 or ATRA to BD4 ratio
was increased to 5:1. These data suggest that the affinity of BD4 binding to RARa is higher than Am580 and ATRA.
doi:10.1371/journal.pone.0027945.g003
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markers in these partially differentiated podocytes. We found that
BD4 significantly stimulates the expression of synaptopodin,
nephrin and WT1 to levels similar what has been previously
observed with ATRA or Am480 at the same concentration (1 mM)
(Figure 5A). As a control, we also examined the expression of
RARa and RARb in these cells. We found that BD4 increases the
mRNA of RARb without changing the expression of RARa,
which is similar to what we had observed previously with ATRA
and Am580 [23] (Figure 5B). It is well known that RARb, but not
RARa, is a target gene of retinoid acid response element (RARE)
[40].
5. Determine the effects of BD4 in HIV-1 transgenic mice
(Tg26)
We previously demonstrated that treatment of Tg26 mice with
Am580 ameliorates kidney disease. To determine the effect of
BD4 on the development of kidney disease in Tg26 mice, we
treated Tg26 mice with either vehicle or BD4 by daily gavages
from age of 4 weeks, which is approximately the age when Tg26
animals develop significant proteinuria. After 6 weeks of
treatment, these mice were sacrificed. Serum was collected and
blood urea nitrogen (BUN), as a marker of glomerular function,
was measured. Urine samples were collected for determination of
albumin and creatinine and albumin/creatinine ratio was
calculated. Kidney samples were fixed then paraffin-embedded.
Glomeruli were isolated from kidneys. mRNA levels of markers for
differentiated podocytes were determined by real-time PCR using
total RNA extracted from isolated glomeruli.
We found that BD4 significantly reduced BUN and proteinuria
in Tg26 mice compared to those treated with vehicle (Table 1).
We also confirmed that kidney injury (glomerulosclerosis and
tubule-interstitial fibrosis) was also significantly improved with
BD4 (Table 1 and Figure 6). In addition, BD4 treatment restored
the expression of podocyte-specific markers—synaptopodin,
nephrin and WT1 (figure 7A). Consistent with our previous
findings [23], BD4 also increased mRNA levels of RARb in both
WT and Tg26 glomeruli while RARa expression unaffected
(Figure 7B). Taken together these data suggest that BD4 attenuates
kidney injury and improves podocyte differentiation in Tg26 mice.
These beneficial effects of BD4 in Tg26 mice are similar to those
we had previously reported for Tg26 mice treated with ATRA and
Am580.
Discussion
The treatment of kidney glomerular disease is challenging.
Many lines of evidence suggest that retinoic acid can improve
kidney injury in animal models of kidney disease [9]. However,
long-term clinical use of retinoids in patients with kidney disease is
difficulty due to significant side effects. A phase II clinical study
approved by NIH has not been completed likely because of
recruitment issues (NIDDK website). Recently, we have shown
that the beneficial effects of ATRA for treatment of kidney disease
in HIV1 trangenic mice are mediated through the activation of
RARa [23]. RARa agonists can reduce proteinuria and
glomerulosclerosis and protect podocytes from injury [23]. Our
previous data suggest that Am580 can improve kidney injury in
HIV-1 transgenic mice [23]. It is known that Am580 may have
less toxicity than ATRA because most side effects of ATRA are
likely mediated by activation of RARc [41] [42]. However,
significant side effects are still reported with Am580 [42].
Therefore, further discovery of better RARa agonists are
warranted.
In this study, we have established the efficacy of a novel
synthetic retinoid, BD4, in ameliorating the development of kidney
disease in Tg26. BD4 should have a more favorable side-effect
profile based on its molecular structure. The low cellular toxicity in
cultured podocytes and the lack of increase in morbidity and
mortality in the BD4-treated animals suggest that BD4 is not toxic.
However, the effect of BD4 on other known side effects of retinoids
including teratogenicity, dyslipidemia, depression, dry skin, and
inflammatory bowel disease will need to be further investigated.
Although our data suggest that RARa agonists reduce kidney
injury in HIV-1 transgenic mouse, a model for HIVAN. Based on
previous studies, we believe that RARa agonists would also protect
against podocyte injury in other forms of glomerular diseases. Our
unpublished data suggest that Am580 also protects against diabetic
nephropathy in mice.
Based on these findings, we conclude that BD4, a new RARa
agonist, induces podocyte differentiation in vitro and improves
proteinuria and glomerulosclerosis of HIV-1 transgenic mice in
vivo. BD4 might also protect against other forms of glomerular
diseases such as FSGS and diabetic kidney disease. The toxicity
and side-effect profile of BD4 will need to be investigated further
prior to clinical trials in human subjects.
Methods
1. Synthesis of BD4
All reagents were purchased from commercial sources unless
otherwise indicated. Products were purified by column chroma-
tography over silica gel.
1H NMR and
13C NMR spectra were
recorded at 25 uC at 300 MHz and 75 MHz, respectively, with
TMS as internal standard. Abbreviations for signal coupling are as
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br,
broad. Column chromatography was performed using SiO2
Figure 4. Cell toxicity assay. Mouse podocytes cultured at 37uC for
10 days and then treated with ATRA, Am580, or BD4 at the different
concentrations for 24 hours in serum free medium. Cell death was
quantified by trypan blue staining, n=6, *p,0.01 compared to cells
treated with DMSO, **p,0.05 compared to cells treated with either
ATRA or Am580 at corresponding concentrations.
doi:10.1371/journal.pone.0027945.g004
Role of Retinoids in HIV-Associated Nephropathy
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27945(0.040 – 0.063 mm, 230 – 400 mesh ASTM) from Merck. Mass
spectra were recorded on Varian MS mass spectrometer. To the
stirred solution of aldehyde B (compound B in Figure 1, 400 mg,
1 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaboratophenyl)-
methyl triphenylphosphonium bromide (compound C in
Figure 1, 880 mg, g, 2 mmol) in anhydrous DMF was added
and stirred. Sodium tert-butoxide (0.38 g, 0.003 mmol) was added
to the solution at 0uC and allowed it to stir in RT for 12 h. The
deep brown color reaction mixture was poured into water (20 mL)
and extracted with ethylacetate (3610 mL).The organic layer was
washed with H2O, brined and dried over anhydrous Na2SO4 and
filtered. Evaporation of the solvent followed by column chroma-
tography on silica gel using 5% ethylacetate/hexane afforded pure
olefin as yellow solid BJ1(BD4) (480 mg, 73%). Compound BD4
has the following spectral signature:
1H NMR (300 MHz, CDCl3):
d 7.77 (d, J=9.0 Hz, 2H), 7.52-7.48 (m, 2H), 7.42 (d, , J=9.0 Hz,
2H), 7.33 (dd, J12=3.0 Hz, J13=9.0 Hz, 3H), 7.13 (d, J=3.0 Hz,
1H), 7.07 (d, J=15.0 Hz, 1H), 7.01(d, J=3.0 Hz, 1H), 6.74 (s,
1H), 6.51(d, J=15.0 Hz, 1H), 6.40(s, 1H), 1.37(s, 12H);
13C NMR
(75 MHz, CDCl3): d 146.9, 139.4, 137.7, 135.5, 134.9, 131.4,
129.3, 129.2, 129.0, 127.9, 127.8, 126.5, 126.3,125.7, 125.0,
123.6, 122.7, 84.2, 77.6, 25.2 ESI MS: [M+H] 505.1352, Calcd
504.1430 for C29H27BCl2O3
2. RARa ligand binding assay
Our lead molecule BD4 contains a boronic acid group. For
tritiation reaction, Ruthenium (Ru) and other organometallic
catalysts are required to introduce tritium inside the phenyl ring
system. Since the boronic-ester group is very prone to demetala-
tion in the presence of organometalic catalysts and also it may
Figure 5. Expression of podocyte differentiation markers in vitro. A. Mouse podocytes cultured at 37uC for 10 days and then stimulated with
either ATRA, or Am580, or BD4 at 0.1 mM and 1 mM for 24 hours in serum free medium. Total RNA was extracted and analyzed by real-time PCR to
determine the expression of podocyte differentiation markers (synaptopodin, nephrin, and WT-1). B. Podocytes stimulated with either ATRA, or
Am580, or BD4 at 1 mM for 24 hours in serum free medium. Real-time PCR analysis of RARa and RARb expression were performed. The ratios of these
genes normalized to GAPDH expression are expressed. N=4, p*,0.01 compared to cells treated with DMSO.
doi:10.1371/journal.pone.0027945.g005
Table 1. Effects of BD4 on mouse body weight, BUN, proteinuria, and kidney histology.
Body Weight BUN (mg/dl) Albumin/Cr ratio GS index Podocyte Hypertrophy Tubular casts/cysts
WT + Vehicle 22.660.8 24.662.4 0.1260.10 0 0 0
Tg26 + Vehicle 21.661.8 39.663.4 3.3461.56 18.5611.1 1.260.8 9.465.6
WT + BD4 22.261.2 25.463.2 0.1860.22 0 0 0
Tg26 + BD4 21.362.3 28.563.8* 0.3461.5* 2.760.78* 0.360.5* 1.460.9*
Tg26 and the WT littermates were treated with BD4 or control DMSO for 6 weeks. Body weight was recorded when mice were sacrificed. Blood samples were collected
for measurement of BUN and urine samples were collected for determination of albumin and creatinine. Histology of these kidneys was analyzed as described in the
method, n=6,
*p,0.01 compared to Tg26 mice treated with vehicle.
doi:10.1371/journal.pone.0027945.t001
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with tritium. Labeling of BD4 with a fluorescence tag is also
problematic. Since BD4 is a small molecule, tagging it with a
fluorescence marker has a high potential to interfere with its
binding to RARa. To overcome these challenges, we used a
modified version of a fluorometric binding assay that has been
previously described [37]. First, we determined the fluorescence
spectrum of BD4 in the range of excitation wavelength from
300 nm to 450 nm and emission wavelength from 350 nm to
500 nm. An emission peak of 480 nm was found at the excitation
wavelength of 380 nm. There was very low baseline emission
reading at this wavelength. A linear relationship was observed
between the amount of BD4 and fluorescence emission at 480 nm.
This allowed us to develop a fluorometric assays to assess BD4
binding to RARa. Purified RARa was generated using a bacterial
expression system. First, RARa cDNA was subcloned into pGEX
bacterial expression construct and GST-RARa fusion protein was
purified from bacterial lysate using GST affinity columns as
described previously [21]. For BD4 binding experiments, different
concentrations of BD4 were mixed with 2610
27 M of purified
GST-tagged RARa at 37uC for 10 minutes and emission at
480 nm was measured with excitation of 380 nm. Since the
addition of albumin, GST, or GST-RARa into BD4 solution did
not change the fluorometric reading at baseline, we decided to
precipitate GST-RARa-bound BD4 by glutathione beads and
removed them by centrifugation. This allowed us to measure the
fluorescence of unbound BD4 in the supernatant. Similar
experiments were performed with GST as a non-specific control
for BD4 binding. Based on these data, we were able to calculate
the fraction of BD4 bound to RARa by subtracting the unbound
BD4 (after precipitation) from total BD4 fluorescence (before
precipitation). A scatter curve between BD4 concentrations and
the percentage of RARa2bound BD4 was built to calculate the
affinity of binding (KD).
Next, we determined the binding affinity of Am580 and ATRA
to RARa. Since Am580 and ATRA do not have the same
fluorometric activity as BD4 (Ex 380 nm and Em 480 nm), we
performed competitive binding assays by incubating varying
concentrations of either Am580 or ATRA to compete with BD4
for binding to GST-RARa ˜ Fluorometric measurements at 480 nm
Figure 7. Expression of podocyte differentiation markers in vivo. Glomeruli were isolated from both WT and Tg26 mice treated with vehicle
or BD4 for 6 weeks. Total RNA was isolated from the glomeruli for real-time PCR analysis for the podocyte differentiation markers including
synaptopodin, nephrin, and WT-1 (A) as well as for RARa and RARb (B). The ratio of these genes normalized to GAPDH was calculated. n=6, *p,0.01
compared to vehicle-treated WT mice (WT-vehicle), **p,0.05 compared to vehicle-treated Tg26 mice (Tg26-vehicle), ***p,0.05 compared to vehicle-
treated WT mice (WT-vehicle).
doi:10.1371/journal.pone.0027945.g007
Figure 6. Kidney histology. Both Tg26 and WT mice were fed with
either control vehicle or BD4 by daily gavage from 4 to 12 weeks of age.
Mice were sacrificed at 12 weeks of age and the kidneys were removed
for histology analysis. The representative H&E stained sections from six
mice in each group are shown.
doi:10.1371/journal.pone.0027945.g006
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RARa and estimate the relative affinity of RARa to BD4, Am580,
and ATRA.
3. Podocyte cultures and in vitro studies
Podocyte cell culture: Conditionally immortalized murine
podocytes are gifts from Dr. Peter Mundel (Massachusetts General
Hospital, Boston). To permit immortalized growth, the culture
medium was supplemented with 10 units/mL of recombinant
mouse c-interferon to induce the expression of T antigen and cells
were cultured at 33uC (permissive conditions). To induce
differentiation, cells were cultured on type I or collagen IV at
37uC without c-interferon for at least 10 days. We confirmed the
degradation of the T antigen under nonpermissive condition
(37uC) by Western blot analysis. Partially differentiated podocytes
at 37uC were used in all cell culture experiments. Cells were
stimulated with either ATRA, or Am580, or BD4 at the different
doses for 24 hours in the serum-free medium. Then, cells were
harvested for total RNA isolation and real-time PCR analysis of
podocyte-specific gene expression.
4. Animal studies
HIV-1 transgenic mice (Tg26) and their age-matched corre-
sponding littermates (n=6 per group including 3 male and 3
female mice in each group) were fed with either control vehicle or
BD4 by daily garvage at a concentration of 0.3 mg/kg/day. The
mice were fed with this compound everyday from age of 4 weeks
to 10 weeks. Unrestricted food and water were provided
throughout the duration of the experiment. The mice were
euthanized at 10 weeks of age for blood, urine, and tissue
collection by exposure to carbon monoxide. Body and kidney
weight were recorded. All animal studies were performed
according to the protocols approved by Institutional Animal
Care and Use Committee at the Mount Sinai School of Medicine
(GCO#06-1098).
5. Measurement of BUN, urine protein, and creatinine
Blood urea nitrogen (BUN) was measured by using a
commercially available kit (Bioassay Systems, Hayward, CA).
Urine albumin was quantified by ELISA using a kit from Bethyl
Laboratory Inc. (Houston, TX, USA). Urine creatinine levels were
measured in the same samples using QuantiChrom
TM Creatinine
Assay Kit (DICT-500) (BioAssay Systems) according to the
manufacturer instruction. The urine albumin excretion rate was
expressed as the ratio of albumin to creatinine.
6. Quantitative Histopathology
Mice were perfused with PBS containing 4% paraformaldehyde
and kidneys were further fixed in 4% paraformaldehyde for
2 hours. Kidney tissue was embedded into paraffin. Kidney
histology was examined after periodic acid-Schiff (PAS) staining.
Glomerulosclerosis was scored as described previously by Dr.
D’Agati [43]. Briefly, each specimen received a score for three
parameters: percentage of collapsing glomerular sclerosis, per-
centage of tubular cysts or casts, and podocyte hypertrophy. The
percentage of collapsing glomerulosclerosis was obtained by
identifying the total number of glomeruli with any sclerosis and
dividing this number by the total number of glomeruli seen. The
percentage of tubular cysts or casts score was obtained by the
number of tubules with either microcystic dilatation or filled with
casts divided by the total number of tubular cross sections in a
representative area. Finally, the degree of podocyte hypertrophy
was scored as 0 (absence), 1+ (podocyte hypertrophy observed in
less than 25% of all glomeruli), 2+ (podocyte hypertrophy
observed in between 25–50% of all glomeruli), and 3+ (podocyte
hypertrophy in greater than 50% of all glomeruli).
7. Isolation of glomeruli from mice for western blot and
real-time PCR
Mouse glomeruli were isolated as described [44]. Briefly,
animals were perfused with Hank’s Buffered Salt Solution (HBSS)
containing 2.5 mg/ml iron oxide and 1% bovine serum albumin.
At the end of perfusion, kidneys were removed, decapsulated,
minced into 1-mm
3 pieces, and digested in HBSS contain-
ing1 mg/ml collagenase A and 100 U/ml deoxyribonuclease I.
Digested tissue was then passed through 100 micron cell strainer
and collected by centrifugation. The pellet was resuspended in
2 ml of HBSS and glomeruli were collected using a magnet. The
purity of glomerular was verified under microscopy and by
western blot analysis for podocyte specific markers including
synaptopodin, nephrin, and WT-1.
8. Real-time PCR
Total RNA was isolated from kidney glomeruli of mice using
TRIzol (Invitrogen). Real-time PCR was performed with a Roche
Lightcycler and Qiagen QuantiTect One Step RTPCR SYBR
green kit(Qiagen)according tothemanufacturer’sinstructions. Pre-
designed primer sets were obtained from Qiagen (GeneGlobe) for
synaptopodin, nephrin, WT-1, RARa, RARb, and GAPDH. The
sequences of the primers are summarized in the Table 2. Light
cycler analysis software was used to determine crossing points using
the second derivative method. Data were normalized to house-
keeping genes (GAPDH) and presented as fold increase compared
to RNA isolated from WT animals using the 2
2DDCT method.
9. Statistical Analysis
Data were expressed as mean 6 standard deviation (X6SD).
The unpaired T-test was used to analyze data between two groups.
Table 2. Sequences of the primers.
Gene name sense antisense
Synaptopodin 59-GACACCGTTTCCTCTCCGC 59-AGAAAAGCGTCAGACAGCAGT
Nephrin 59- GTGCCCTGAAGGACCCTACT 59-CCTGTGGATCCCTTTGACAT
WT-1 59-GAGAGCCAGCCTACCATCC 59-GGGTCCTCGTGTTTGAAGGAA
RARa 59-CGCTCCGGACTCCGCTTTGG 59-CCCTTGCAGCCCTCACAGGC
RARb 59-ACCGAATGGCAGCATCGGCA 59-TCCCTCACAGGCGCTGACCC
GAPDH 59-TGTTGCCATCAATGACCCCTT 59-CTCCACGACGTACTCAGCG
doi:10.1371/journal.pone.0027945.t002
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between the groups was further analyzed using Bonferroni
correction. The renal scoring data was analyzed by using non-
parametric Wilcoxon Signed Rank Test. Statistical significance
will be considered when p,0.05.
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